Microvast Holdings announces departure of chief financial officer
IRVINE, Calif. - Edwards Lifesciences (NYSE:EW) reported fourth quarter earnings and revenue that beat analyst expectations, sending its shares up 4.2% in after-hours trading on Tuesday.
The medical device maker posted adjusted earnings per share of $0.59, topping the consensus estimate of $0.55. Revenue grew 9.4% year-over-year to $1.39 billion, exceeding analyst projections of $1.36 billion.
Edwards’ Transcatheter Aortic Valve Replacement (TAVR) sales, its largest segment, rose 5.8% to $1.04 billion in Q4. The company’s fast-growing Transcatheter Mitral and Tricuspid Therapies division saw sales surge 87.7% to $105.1 million.
"It was a year of meaningful progress for Edwards in 2024, as our 16,000 employees advanced life-saving structural heart innovations for patients around the world," said Bernard Zovighian, Edwards’ CEO.
Looking ahead, Edwards provided upbeat guidance for Q1 2025, projecting revenue between $1.35-$1.43 billion and adjusted EPS of $0.58-$0.64. Both ranges were largely above Wall Street expectations.
The company reiterated its full-year 2025 outlook for constant currency sales growth of 8-10% and adjusted EPS of $2.40-$2.50.
Edwards continues to expect mid-year approval in the U.S. for its TAVR therapy to treat asymptomatic severe aortic stenosis patients, which could further boost growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.